Scarica l'app Stockscreener
0.8615
4.70%
0.0387
Precedente Chiudi:
$0.8228
Aprire:
$0.8
Volume 24 ore:
52,619
Relative Volume:
0.59
Capitalizzazione di mercato:
$38.16M
Reddito:
$15.97M
Utile/perdita netta:
$-24.40M
Rapporto P/E:
-1.1358
EPS:
-0.7585
Flusso di cassa netto:
$-45.82M
1 W Prestazione:
+8.50%
1M Prestazione:
-0.78%
6M Prestazione:
-20.96%
1 anno Prestazione:
-4.91%
Intervallo 1D:
$0.00
$0.00
Intervallo di 1 settimana:
$0.7628
$0.8615
Portata 52W:
$0.50
$1.385
Elutia Inc Stock (ELUT) Company Profile
Nome
Elutia Inc
Settore
Industria
Telefono
240-247-1143
Indirizzo
12510 PROSPERITY DRIVE, SILVER SPRING
Compare ELUT vs ABT, MDT, SYK, BSX, EW
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ELUT
Elutia Inc
|
0.8615 | 38.16M | 15.97M | -24.40M | -45.82M | -0.7585 |
ABT
Abbott Laboratories
|
102.51 | 177.38B | 46.59B | 5.41B | 7.38B | 3.0938 |
MDT
Medtronic Plc
|
96.59 | 123.55B | 36.36B | 4.84B | 5.43B | 3.7261 |
SYK
Stryker Corp
|
307.08 | 117.79B | 25.27B | 3.34B | 4.57B | 8.6334 |
BSX
Boston Scientific Corp
|
46.01 | 66.68B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
90.09 | 51.93B | 6.30B | 1.07B | 1.09B | 1.8406 |
Elutia Inc Stock (ELUT) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2020-11-02 | Iniziato | Cantor Fitzgerald | Overweight |
| 2020-11-02 | Iniziato | Cowen | Outperform |
| 2020-11-02 | Iniziato | Piper Sandler | Overweight |
| 2020-11-02 | Iniziato | Truist | Buy |
Elutia Inc Borsa (ELUT) Ultime notizie
Elutia Receives $8 Million Payment from Boston Scientific; Company Now Fully Funded into 2029 - The Manila Times
The buyer releases $8 million held back from Elutia's sale. Elutia believes funding extends into 2029. - stocktitan.net
Elutia Receives $8 Million Payment from Boston Scientific; Company Now Fully Funded into 2029 - GlobeNewswire
Press Release: Elutia Receives $8 Million Payment From Boston Scientific; Company Now Fully Funded Into 2029 - Moomoo
ELUT 8-K及美國證券交易委員會申報文件 - Yahoo 財經
ELUT: Drug-eluting biomatrix targets surgical infections, with strong demand and full funding to launch - TradingView
Elutia at H.C. Wainwright conference: capital, data and launch path By Investing.com - Investing.com India
Elutia at H.C. Wainwright conference: capital, data and launch path By Investing.com - Investing.com Canada
Elutia at H.C. Wainwright conference: capital, data and launch path By Investing.com - Investing.com UK
Elutia to Present at the H.C. Wainwright 28th Annual Global Investment Conference on September 15th - marketscreener.com
Elutia will discuss how to address infections after reconstructive surgery - Stock Titan
Post-surgical infections will be discussed at Elutia's upcoming talks - Stock Titan
Elutia (ELUT) Holds Steady at $0.88 as Shares Consolidate Between Support and ResistanceCall Wall - dars.gov.et
Elutia Inc. Earnings Call Highlights Funding, NXT Outlook - TipRanks
Elutia (ELUT) Move: Moves 2.32% Lower to $0.90; Price Levels: Traders Can Monitor the $0.85-$0.95 Range under the Current SnapshotSwing Entry Signals - vinanet.vn
Elutia (ELUT) Move: Moves 2.32% Lower to $0.90; Price Levels: Traders Can Monitor the $0.85-$0.95 Range under the Current SnapshotStock Picks - siam.in
Elutia (ELUT) Q2 2026 Earnings Call Transcript - The Globe and Mail
Elutia Completes SimpliDerm® Sale on Schedule, Adds $8 Million in Cash to Fund NXT-41x Through Full Commercial Launch - Sahm
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Gain Therapeutics (GANX), Summit Therapeutics (SMMT) and Elutia (ELUT) - The Globe and Mail
Cellution Biologics Acquires SimpliDerm From Elutia for Up to $11 Million - citybiz
ELUT Looks 5.6% Overvalued on GF Value™ - GuruFocus
Cellution Biologics Completes Acquisition of SimpliDerm® from Elutia Inc. - The Manila Times
Cellution Biologics Completes Acquisition of SimpliDerm® from Elutia Inc. - mykxlg.com
Elutia Flat on Sale to Cellution - Baystreet.ca
Elutia Flat on Sale to Cellution - Baystreet.ca
Elutia sells SimpliDerm business for up to $11 million - Investing.com
Elutia sells SimpliDerm business for up to $11 million By Investing.com - Investing.com India
Elutia sells SimpliDerm business for up to $11 million By Investing.com - Investing.com Canada
Elutia gets $8 million at closing as FDA clearance is expected in 2027 - Stock Titan
Elutia Completes SimpliDerm® Sale on Schedule, Adds $8 Million in Cash to Fund NXT-41x Through Full Commercial Launch - The Manila Times
Elutia Completes SimpliDerm® Sale on Schedule, Adds $8 - GlobeNewswire
SILVERARC CAPITAL MANAGEMENT, LLC Trims Elutia Inc (ELUT) Stake -- Shares Look 11% Overvalued on GF Value - GuruFocus
Cellution Biologics Llc completed the acquisition of SimpliDerm human acellular dermal matrix business of Elutia Inc. for $11 million. - marketscreener.com
Elutia (ELUT) Q2 2026 Earnings: Wider-Than-Expected Loss as Shares Advance 1.49%Earnings Outlook Update - vinanet.vn
Elutia (ELUT) Q2 2026 Earnings: Wider-Than-Expected Loss as Shares Advance 1.49%Estimate Dispersion - dars.gov.et
Elutia Inc (ELUT) Stock News Today - TradingKey
Elutia Inc. 2026 Q2ResultsEarnings Call Presentation (NASDAQ:ELUT) 2026-08-16 - Seeking Alpha
Downgrade: What You Need To Know About The Latest Elutia Inc. (NASDAQ:ELUT) Forecasts - simplywall.st
Downgrade: What You Need To Know About The Latest Elutia Inc. (NASDAQ:ELUT) Forecasts - simplywall.st
Elutia secures $26M to launch NXT-41x, targetin... - Pluang
Elutia Secures Up to $26 Million to Fund NXT-41x Through Commercial Launch; Reports Second Quarter 2026 Results - Sahm
Elutia Q2 2026 slides: $26M capital raise funds NXT41x launch - Investing.com Australia
Elutia Inc. (ELUT): SilverArc Capital reports 4.9% stake in Class A shares - Stock Titan
Elutia Inc. Q2 2026 Earnings Call Summary - Yahoo Finance
Elutia Inc (ELUT) (Q2 2026) Earnings Call Highlights: Strategic - GuruFocus
Elutia Inc (ELUT) (Q2 2026) Earnings Call Highlights: Strategic Pivot to NXT41X Drives Strong ... By GuruFocus - Investing.com Canada
ELUT Looks 2.2% Undervalued on GF Value™ Amid Challenging Sales and Cash Flow - GuruFocus
Elutia Q2 2026 slides: $26M capital raise funds NXT41x launch - Investing.com India
Elutia Q2 2026 slides: $26M capital raise funds NXT41x launch - Investing.com South Africa
Elutia Inc. (NASDAQ: ELUT) Share Price, ELUT Stock News, ELUT Share Price & Updates - kalkine.ca
Elutia Inc Azioni (ELUT) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Elutia Inc Azioni (ELUT) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| NEELS GUIDO J | Director |
Jan 30 '26 |
Buy |
1.04 |
20,000 |
20,800 |
118,750 |
| NEELS GUIDO J | Director |
Jan 29 '26 |
Buy |
1.06 |
15,000 |
15,900 |
98,750 |
| NEELS GUIDO J | Director |
Jan 28 '26 |
Buy |
1.06 |
15,000 |
15,900 |
83,750 |
| William Matthew Zuga | Former Director |
Dec 23 '25 |
Proposed Sale |
0.55 |
12,613 |
6,937 |
0 |
| RAKIN KEVIN | Director |
Dec 17 '25 |
Buy |
0.52 |
50,000 |
25,995 |
322,419 |
| Colpman David | Director |
Dec 17 '25 |
Buy |
0.51 |
12,500 |
6,375 |
31,098 |
| Makes Brigid | Director |
Dec 17 '25 |
Buy |
0.52 |
25,000 |
13,000 |
27,000 |
| Mills C Randal | PRESIDENT AND CEO |
Dec 17 '25 |
Buy |
0.51 |
3,000 |
1,530 |
379,204 |
| Ferguson Matthew | CHIEF FINANCIAL OFFICER |
Dec 17 '25 |
Buy |
0.53 |
60,000 |
31,800 |
447,110 |
| Ferguson Matthew | CHIEF FINANCIAL OFFICER |
Dec 02 '25 |
Buy |
0.67 |
5,500 |
3,685 |
379,071 |
0.00%
1.86%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):